Investments in the project will amount about 3.2 billion rubles, as it was said by company's founder.
This company will include a full cycle of production: the processing of blood from beginning to end with its subsequent encapsulation.
According to initial estimates, the production revenue will be 2.5 billion rubles, the planned output is planned at 500,000 packs per year (blood substitutes, blood coagulation factors, intravenous immunoglobulins, a substance based on human blood proteins, innovative
The company is able to provide the population of Russia with high-quality and safe medicines. The company will provide over 200 jobs. Applicants will be subject to increased demands.
It is supposed that the planned scheme of the building will include a research and production department, a section for storing products and production itself.